¼¼°èÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå-¼ºÀå, ÇâÈÄ Àü¸Á, °æÀï ºÐ¼®(2023-2031³â)
Implantable Infusion Pumps Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
»óǰÄÚµå : 1313698
¸®¼­Ä¡»ç : Acute Market Reports
¹ßÇàÀÏ : 2023³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 116 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,274,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,500 £Ü 9,062,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 9,000 £Ü 12,548,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»ðÀÔÇü ÁÖÀÔ ÆßÇÁ(Implantable Infusion Pumps) ½ÃÀåÀº 2031³â±îÁö 5.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ½Ä °¡´ÉÇÑ ÁÖÀÔ ÆßÇÁ´Â ÀÎüÀÇ Æ¯Á¤ ºÎÀ§¿¡ ¾à¹°À» Àü´ÞÇϱâ À§ÇØ ¼ö¼úÀûÀ¸·Î ÇÇÇÏ¿¡ À̽ÄÇÏ´Â ¼ÒÇü ÀåÄ¡À̸ç ÅëÁõÀ» ÁÙÀ̱â À§ÇØ ¿¡ Ç¥ÀûÀ» Á¼Èù ÀϰüµÈ ¾à¹°À» Á¦°øÇÕ´Ï´Ù. »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå ¼ö¿ä Áõ°¡¸¦ µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ³ëÀÎ Àα¸ Áõ°¡, ¸¸¼º Áúȯ È®»ê, °Ç°­ °ü¸® ¼­ºñ½º Á¢±Ù, ¹Î°£ º´¿ø Áõ°¡ÀÔ´Ï´Ù. °Ç°­ ÀǽÄÀÇ Çâ»ó¿¡ ÀÇÇØ, ¼±Áø±¹, °³¹ßµµ»ó±¹À» ºÒ¹®ÇÏ°í ³ë³â Àα¸°¡ Áõ°¡Çϰí ÀÖ¾î, ±× °á°ú, ÀÔ¿øÀ²ÀÌ »ó½ÂÇØ, ÀÓÇöõÆ® ¼ö¼úÀÇ °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ÈÄ ÅëÁõ °ü¸®¸¦ ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º ÁúȯÀÌ ³Î¸® È®»êµÇ´Â °ÍÀº ¶ÇÇÑ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀåÀÇ ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. °Ç°­ º¸Çè ȸ»ç´Â Áúº´ ȯÀÚ°¡ ´õ ³ªÀº °Ç°­ °ü¸® ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀǷᡤº¹Áö¿¡ °Å¾×ÀÇ ÁöÃâÀ» ½Ç½ÃÇÏ´Â ¹Î°£ º´¿ø Áõ°¡¿Í Áö¹æ¿¡ÀÇ È®´ë´Â »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå ħÅõ¿¡ È£¿µÇâÀ» ÁÝ´Ï´Ù. ±×·¯³ª ÀÌ ½Ã³ª¸®¿ÀÀÇ °úÁ¦´Â ¾à¹°ÀÇ ±Ý´Ü Áõ»ó, ÀÓÇöõÆ® ºÎÀ§ÀÇ ÅëÁõ°ú °¨¿°, ÀÓÇöõÆ®¿Í °ü·ÃµÈ ±â°èÀû ¹®Á¦(±â¾î Á¤Áö, ¹èÅ͸® ºÎÁ·)·Î ÀÎÇÑ ÀáÀçÀû ÇÕº´ÁõÀ¸·Î ½É°¢ÇÑ ºÎ»óÀ» ÃÊ·¡ÇÕ´Ï´Ù. °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå¿¡ ´ëÇÑ ¾ïÁ¦ ¿äÀÎÀº ¸ðÈ£ÇÑ »óȯ, Àåºñ º¹À⼺À¸·Î ÀÎÇÑ ºó¹øÇÑ Á¦Ç° ¸®ÄÝÀÔ´Ï´Ù. ¸ðÈ£ÇÑ »óȯ Á¤Ã¥Àº ¾à¹° ÀÓÇöõÆ®ÀÇ ¼­ºñ½º¸¦ ÇÊ¿ä·Î ÇÏ´Â Áúº´¿¡ ´ëÇÑ ºñ¿ë º¸»ó ¼­ºñ½º Â÷º°À» ¾ß±âÇϰí, °Ç°­ °ü¸® ¿µ¿ª¿¡¼­ ÁöÃâÀÇ °¡Àå Å« Àå¾Ö¹°ÀÌ µÇ¾ú½À´Ï´Ù. ÆßÇÁ ¼³°è°¡ º¹ÀâÇÏ°í ¾à¹°Àü´Þ ¹®Á¦°¡ ¹Ýº¹µÇ±â ¶§¹®¿¡ Á¦Ç° ¸®ÄÝÀÌ ÀÚÁÖ ¹ß»ýÇϰí Á¦Ç° ¿¬±¸ °³¹ß¿¡ ¸¹Àº ºñ¿ëÀÌ µì´Ï´Ù. À̰ÍÀº »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀåÀÇ Ä§Åõ¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

ºÏ¹Ì¿Í À¯·´¿¡¼­´Â À§Àå ÇÕº´Áõ, ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ¾Ï µî ÁÖ¿ä ¸¸¼º ÁúȯÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Áúº´¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô°í ħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ À̵é Áö¿ª¿¡¼­ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ´ë±â¾÷ÀÇ °æÀïÀÌ ½ÉÇϰí Á¦Ç° ȸ¼öÀÇ °¡´É¼º°ú ȯÀÚÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ ¾Ç¿µÇâÀ» ÁÙÀ̱â À§ÇØ ¼³°è ¹× ÀÀ¿ë ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ Çõ½ÅÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾ç°ú Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â Áï°¢ÀûÀÎ ÀÇ·á °³ÀÔÀÌ ÇÊ¿äÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ ³ôÁö¸¸ Áúº´¿¡ ´ëÇÑ ÀνÄÀÌ ³·¾Æ ÀáÀçÀûÀÎ ½ÃÀåÀÔ´Ï´Ù. ¿Üµý Áö¿ª°ú Áصµ½Ã Áö¿ªÀÇ ¹Ì°³Ã´ ½ÃÀåÀ» °ø·«ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Codman and Shurtleff(CODMAN 3000)¿Í °°Àº Á¦Á¶¾÷ü´Â ¸¸¼º ÅëÁõ Ä¡·á¸¦ À§ÇØ ÀÏÁ¤ÇÑ À¯·®ÀÇ ¾à¹° Àü´ÞÀ» Á¦°øÇÕ´Ï´Ù. Medtronics´Â Áö¼ÓÀûÀÎ Æ÷µµ´ç ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá Àν¶¸° ÆßÇÁ¸¦ Á¦°øÇÕ´Ï´Ù. »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå¿¡¼­ °üÂûµÇ´Â ÃֽŠÁ¦Ç°Àº »ïÅõ¾Ð ÆßÇÁ(ALZET), dz¼± ÆßÇÁ(Fresenius Kabi AG)ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå : °æÀï ºÐ¼®

Á¦4Àå »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå : °Å½Ã ºÐ¼® ¹× ½ÃÀå ¿ªÇÐ

Á¦5Àå »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå : Á¦Ç°º°(2021-2031³â)

Á¦6Àå »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå : ¿ëµµº°(2021-2031³â)

Á¦7Àå »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2021-2031³â)

Á¦8Àå ºÏ¹ÌÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå(2021-2031³â)

Á¦9Àå ¿µ±¹ ¹× À¯·´ ¿¬ÇÕÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå(2021-2031³â)

Á¦10Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå(2021-2031³â)

Á¦11Àå ³²¹ÌÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå(2021-2031³â)

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ »ðÀÔÇü ÁÖÀÔ ÆßÇÁ ½ÃÀå(2021-2031³â)

Á¦13Àå ±â¾÷ °³¿ä

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Implantable infusion pumps market expected to Grow at 5.2% by 2031, Implantable infusion pumps are compact devices that are surgically implanted under the skin to deliver drug to specific parts of the human body, they provide targeted and consistent medication to reduce pain. The major factorial entities supporting the growth in demand for implantable infusion pumps market are rise in geriatric population, wide prevalence of chronic diseases, access to healthcare services and rise in private sector hospitals. Due to better health awareness there has been rise in geriatric population in both the developed and developing nations as a result the rate of hospitalization has increased the number of implant surgeries. Wide prevalence of chronic diseases requiring post-operative pain management will have a positive impact on the growth of the implantable infusion pumps market. Healthcare insurance companies have made it possible for ailing patients to access to better healthcare services. Rise in private sector hospitals spending huge amount on health and welfare and its expansion to rural areas have a positive impact on the deep market penetration of implantable infusion pumps. However, the challenges in this scenario would be drug withdrawal symptoms, pain and infection at the implant site and potential complications arising because of mechanical problems related to implant (gear stopping, battery dying) would lead to serious injury. Restraints regarding the implantable infusion pumps market are ambiguous reimbursement, frequent product recalls due to complexity of the equipment. Ambiguous reimbursement policies cause service discrimination in the cost coverage for the diseases requiring drug implant services which is the biggest hurdle for the expenditure in the healthcare domain. The complexity in the design of the pump and repetitive failure in the drug delivery of the pumps leading to frequent product recalls have led to huge expenditure on the product R&D. This has a negative impact on the market penetration of implantable infusion pumps market.

In North America and Europe there is an increasing number of major chronic diseases like gastrointestinal complications, cardiovascular diseases, diabetes and cancer, high disease awareness and rising demand for minimally invasive surgery is expected to assist the growth of implantable infusion pumps market in these regions. The pitfall being high degree of competition by major players which urges need for path breaking innovation in design and application to reduce the probability of product recalls and adverse impact on patient safety. Asia-Pacific and Middle East and Africa are potential market due to high prevalence of chronic diseases requiring immediate medical intervention but less disease awareness. The untapped market in the remote and semi-urban areas can be captured.

Manufacturers like Codman and Shurtleff (CODMAN 3000) provides constant flow of drug delivery for treatment of chronic pain. Medtronics provides insulin pumps with continuous glucose monitoring. The latest products observed in the implantable infusion pump market are Osmotic pumps (ALZET), Balloon pumps (Fresenius Kabi AG) are employed for better results.

Key players identified for global implantable infusion pumps market include:

Codman and Shurtleff, I-Flow Corp/Hylard Health, Flowobix Medical, Inc., Medtronic, Tricumed Medizintechnik GmbH., B. Braun Melsungen AG., CareFusion Corporation, Fresenius Kabi AG, Terumo Corporation, Baxter International Inc., Smiths Medical, MOOG Inc., Johnson & Johnson Private Ltd., and Hospira, Inc., Flowonix, The Tandem Diabetes Care And Other Notable Players.

This report offers:

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofImplantable Infusion Pumps market are as follows:

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Implantable Infusion Pumps market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

Application

End User

Region Segment (2021-2031; US$ Million)

Key questions answered in this report:

Table of Contents

1. Preface

2. Executive Summary

3. Implantable Infusion Pumps Market: Competitive Analysis

4. Implantable Infusion Pumps Market: Macro Analysis & Market Dynamics

5. Implantable Infusion Pumps Market: By Product, 2021-2031, USD (Million)

6. Implantable Infusion Pumps Market: By Application, 2021-2031, USD (Million)

7. Implantable Infusion Pumps Market: By End User, 2021-2031, USD (Million)

8. North America Implantable Infusion Pumps Market, 2021-2031, USD (Million)

9. UK and European Union Implantable Infusion Pumps Market, 2021-2031, USD (Million)

10. Asia Pacific Implantable Infusion Pumps Market, 2021-2031, USD (Million)

11. Latin America Implantable Infusion Pumps Market, 2021-2031, USD (Million)

12. Middle East and Africa Implantable Infusion Pumps Market, 2021-2031, USD (Million)

13. Company Profile

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â